|
시장보고서
상품코드
1463099
세계의 위마비 치료제 시장 - 점유율, 규모, 동향, 산업 분석 보고서 : 약제 클래스별, 질환 클래스별, 최종 사용자별, 지역별, 부문별 예측(2024-2032년)Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024- 2032 |
||||||
Polaris Market Research의 최근 조사에 따르면 위마비 치료제 세계 시장 규모는 2032년까지 66억 6,235만 달러에 이를 것으로 예상됩니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
위마비 치료제 시장은 수요 증가와 시장 확대에 기여하는 여러 요인에 의해 세계적으로 꾸준한 성장을 이루고 있습니다. 위 배출 지연을 특징으로 하는 위마비는 이환자에게 큰 과제를 가져오고 메스꺼움, 구토, 복부 팽만감, 복부 불쾌감 등의 증상을 일으킵니다. 헬스케어 전문가와 환자 사이에서 이 증상에 대한 인식이 높아짐에 따라 효과적인 치료법에 대한 수요가 계속 증가하고 위마비 치료제 시장을 전진시키고 있습니다.
위마비 치료제 시장 성장의 주요 원동력 중 하나는 위마비를 포함한 위장 장애의 유병률이 증가하는 것입니다. 식습관의 변화, 앉기 쉬운 라이프 스타일, 당뇨병의 이환율의 상승에 따라 위마비의 이환율은 세계적으로 상승 경향에 있습니다. 이러한 환자 수의 급증은 제약 기업에게 이러한 환자의 암메트 메디컬 요구에 부응하는 신약을 개발·상품화하는 큰 시장 기회를 창출하고 있습니다. 게다가, 특히 선진지역의 고령화도 환자수 증가에 기여하고 있으며, 시장의 성장을 더욱 뒷받침하고 있습니다.
또한 의료기술과 의약품 개발의 진보로 위마비에 대한 혁신적인 치료법의 도입이 진행되고 있습니다. 제약기업은 유효성과 안전성을 향상시킨 신약을 발견·개발하기 위해 연구개발 활동에 많은 투자를 하고 있습니다. 이러한 노력의 결과, 운동 촉진제, 제토제, 위 운동 장애에 관여하는 특정 경로를 표적으로 하는 약제 등 신규 치료제가 출현하고 있습니다. 다양한 치료 옵션을 사용할 수 있게 되면서, 건강 관리 제공업체는 개별 환자의 필요에 따라 치료를 맞춤화할 수 있는 옵션이 늘어나 시장 성장을 가속하고 있습니다.
위마비 치료제 시장 보고서 하이라이트
운동 촉진제 부문은 2023년에 주목할만한 점유율을 차지했는데, 이는 위 근육의 수축과 운동을 촉진하는 능력 때문입니다.
당뇨병성 위마비 부문은 2023년에 최대 점유율을 차지했지만, 이는 사람들의 라이프 스타일과 소비 패턴의 변화로 인한 당뇨병의 현저한 확산으로 인한 것입니다.
약국 부문은 예측 기간 동안 가장 높은 속도로 성장할 것으로 보이지만, 이는 소매 약국 체인의 대폭적인 확대와 환자 접근성에 기인합니다.
당뇨병 유병률 상승과 첨단 의료 인프라의 존재로 북미가 2023년 세계 시장을 석권
주요 시장 기업은 Medtronic Plc, Rhythm Pharmaceuticals, Vanda Pharmaceuticals, Abbott Laboratories, AbbVie Inc., Pfizer Inc. 등입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 위마비 치료제 시장 인사이트
- 위마비 치료제 시장 - 최종 사용자 스냅샷
- 위마비 치료제 시장 역학
- 성장 촉진요인과 기회
- 당뇨병과 노인 인구 증가가 시장 성장을 뒷받침
- 위마비 치료를 위한 신약 규제 당국의 승인이 시장 성장을 가속
- 억제요인과 과제
- 새로운 치료법 선택의 부족과 성장을 억제하는 규제상의 장애물
- 성장 촉진요인과 기회
- PESTEL 분석
- 위마비 치료제 시장의 최종 사용자 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 질병 클래스별 세계 시장
- 주요 조사 결과
- 소개
- 당뇨병성 위마비
- 특발성 위마비
- 수술 후 위마비
- 기타
제6장 약품 클래스별 세계 시장
- 주요 조사 결과
- 소개
- 소화관 운동 촉진제
- 제토제
- 보툴리눔툭신(보톡스) 주사
제7장 최종 사용자별 세계 시장
- 주요 조사 결과
- 소개
- 병원
- 약국
- 클리닉
- 전자상거래
제8장 지역별 세계 시장
- 주요 조사 결과
- 소개
- 위마비 치료제 시장 평가, 지역(2019-2032년)
- 위마비 치료제 시장 - 북미
- 북미 : 위마비 치료제 시장, 질환 클래스별(2019-2032년)
- 북미 : 위마비 치료제 시장, 최종 사용자별(2019-2032년)
- 북미 : 위마비 치료제 시장, 약제 클래스별(2019-2032년)
- 위마비 치료제 시장 - 미국
- 위마비 치료제 시장 - 캐나다
- 위마비 치료제 시장 - 유럽
- 유럽 : 위마비 치료제 시장, 질환 클래스별(2019-2032년)
- 유럽 : 위마비 치료제 시장, 최종 사용자별(2019-2032년)
- 유럽 : 위마비 치료제 시장, 약제 클래스별(2019-2032년)
- 위마비 치료제 시장 - 영국
- 위마비 치료제 시장 - 프랑스
- 위마비 치료제 시장 - 독일
- 위마비 치료제 시장 - 이탈리아
- 위마비 치료제 시장 - 스페인
- 위마비 치료제 시장 - 네덜란드
- 위마비 치료제 시장 - 러시아
- 위마비 치료제 시장 - 아시아태평양
- 아시아태평양 : 위마비 치료제 시장, 질환 클래스별(2019-2032년)
- 아시아태평양 : 위마비 치료제 시장, 최종 사용자별(2019-2032년)
- 아시아태평양 : 위마비 치료제 시장, 약제 클래스별(2019-2032년)
- 위마비 치료제 시장 - 중국
- 위마비 치료제 시장 - 인도
- 위마비 치료제 시장 - 말레이시아
- 위마비 치료제 시장 - 일본
- 위마비 치료제 시장 - 인도네시아
- 위마비 치료제 시장 - 한국
- 위마비 치료제 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 위마비 치료제 시장, 질병 클래스별(2019-2032년)
- 중동 및 아프리카 : 위마비 치료제 시장, 최종 사용자별(2019-2032년)
- 중동 및 아프리카 : 위마비 치료제 시장, 약제 등급별(2019-2032년)
- 위마비 치료제 시장 - 사우디아라비아
- 위마비 치료제 시장 - UAE
- 위마비 치료제 시장 - 이스라엘
- 위마비 치료제 시장 - 남아프리카
- 위마비 치료제 시장 - 라틴아메리카
- 라틴아메리카 : 위마비 치료제 시장, 질환 클래스별(2019-2032년)
- 라틴아메리카 : 위마비 치료제 시장, 최종 사용자별(2019-2032년)
- 라틴아메리카 : 위마비 치료제 시장, 약제 클래스별(2019-2032년)
- 위마비 치료제 시장 - 멕시코
- 위마비 치료제 시장 - 브라질
- 위마비 치료제 시장 - 아르헨티나
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 파트너십/협업/계약/공개
제10장 기업 프로파일
- Abbott Laboratories(US)
- AbbVie Inc.(US)
- Allergan Inc.(US)
- Evoke Pharma(US)
- Medtronic Plc(Ireland)
- Neurogastrx Inc.(US)
- Pfizer Inc.(US)
- Rhythm Pharmaceuticals Inc.(US)
- Salix Pharmaceuticals(US)
- TEVA Pharmaceutical(Israel)
- Vanda Pharmaceuticals Inc.(US)
The global gastroparesis drugs market size is expected to reach USD 6,662.35 Million by 2032, according to a new study by Polaris Market Research. The report "Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The gastroparesis drugs market has been experiencing steady growth globally, driven by several factors contributing to increased demand and market expansion. Gastroparesis, a condition characterized by delayed emptying of the stomach, poses significant challenges for affected individuals, leading to symptoms such as nausea, vomiting, bloating, and abdominal discomfort. As awareness about this condition grows among healthcare professionals and patients alike, the demand for effective treatments continues to rise, propelling the gastroparesis drugs market forward.
One of the primary driving factors behind the growth of the gastroparesis drugs market is the increasing prevalence of gastrointestinal disorders, including gastroparesis. With changing dietary habits, sedentary lifestyles, and rising incidences of diabetes, the incidence of gastroparesis is on the rise globally. This surge in patient numbers has created a substantial market opportunity for pharmaceutical companies to develop and commercialize novel drugs catering to the unmet medical needs of these individuals. Moreover, the aging population, particularly in developed regions, contributes to the growing patient pool, further boosting market growth.
Furthermore, advancements in medical technology and drug development have led to the introduction of innovative treatment options for gastroparesis. Pharmaceutical companies are investing significantly in research and development activities to discover and develop new drugs with improved efficacy and safety profiles. These efforts have resulted in the emergence of novel therapeutic agents, including prokinetic agents, antiemetics, and other drugs targeting specific pathways involved in gastric motility disorders. The availability of a diverse range of treatment options provides healthcare providers with more choices to tailor therapy according to individual patient needs, thereby driving market growth.
Gastroparesis Drugs Market Report Highlights
Prokinetic agents segment accounted for noteworthy share in 2023, that is due to its ability to boost stomach muscles contractions and movement
Diabetic gastroparesis segment held the maximum share in 2023, owing to significant prevalence of diabetes due to change in people lifestyle and consumption patterns
Pharmacies segment will grow at highest pace during forecast period, that is attributed to significant expansion of retail pharmacy chains and easy accessibility to patients
North America dominated the global market in 2023, on account of rising prevalence of diabetes and presence of advanced healthcare infrastructure
The key market players include Medtronic Plc, Rhythm Pharmaceuticals, Vanda Pharmaceuticals, Abbott Laboratories, AbbVie Inc., and Pfizer Inc.
Polaris Market Research has segmented the gastroparesis drugs market report based on drug class, disease class, end user, and region:
Gastroparesis Drugs, Drug Class Outlook (Revenue - USD Million, 2023 - 2032)
- Prokinetic Agents
- Antiemetic Agents
- Botulinum Toxin Injections
Gastroparesis Drugs, Disease Class Outlook (Revenue - USD Million, 2023 - 2032)
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
- Post-surgical Gastroparesis
- Others
Gastroparesis Drugs, End User Outlook (Revenue - USD Million, 2023 - 2032)
- Hospitals
- Pharmacies
- Clinics
- E-commerce
Gastroparesis Drugs, Regional Outlook (Revenue - USD Million, 2023 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Gastroparesis Drugs Market Insights
- 4.1. Gastroparesis Drugs Market - End User Snapshot
- 4.2. Gastroparesis Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising prevalence of diabetes and geriatric population to boost market growth
- 4.2.1.2. Regulatory approvals for new drugs for gastroparesis treatment to boost market growth.
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of novel treatment options and regulatory hurdles to restrain growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Gastroparesis Drugs Market End User Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Gastroparesis Drugs Market, by Disease Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 5.3. Diabetic Gastroparesis
- 5.3.1. Global Gastroparesis Drugs Market, by Diabetic Gastroparesis, by Region, 2019-2032 (USD Million)
- 5.4. Idiopathic Gastroparesis
- 5.4.1. Global Gastroparesis Drugs Market, by Idiopathic Gastroparesis, by Region, 2019-2032 (USD Million)
- 5.5. Post-surgical Gastroparesis
- 5.5.1. Global Gastroparesis Drugs Market, by Post-surgical Gastroparesis, by Region, 2019-2032 (USD Million)
- 5.6. Others
- 5.6.1. Global Gastroparesis Drugs Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Gastroparesis Drugs Market, by Drug Class
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 6.3. Prokinetic Agents
- 6.3.1. Global Gastroparesis Drugs Market, by Prokinetic Agents, by Region, 2019-2032 (USD Million)
- 6.4. Antiemetic Agents
- 6.4.1. Global Gastroparesis Drugs Market, by Antiemetic Agents, by Region, 2019-2032 (USD Million)
- 6.5. Botulinum Toxin Injections
- 6.5.1. Global Gastroparesis Drugs Market, by Botulinum Toxin Injections, by Region, 2019-2032 (USD Million)
7. Global Gastroparesis Drugs Market, by End User
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 7.3. Hospitals
- 7.3.1. Global Gastroparesis Drugs Market, by Hospitals, By Region, 2019-2032 (USD Million)
- 7.4. Pharmacies
- 7.4.1. Global Gastroparesis Drugs Market, by Pharmacies, By Region, 2019-2032 (USD Million)
- 7.5. Clinics
- 7.5.1. Global Gastroparesis Drugs Market, by Clinics, By Region, 2019-2032 (USD Million)
- 7.6. E-commerce
- 7.6.1. Global Gastroparesis Drugs Market, by E-commerce, By Region, 2019-2032 (USD Million)
8. Global Gastroparesis Drugs Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Gastroparesis Drugs Market - North America
- 8.3.1. North America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.3.2. North America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.3.3. North America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.4. Gastroparesis Drugs Market - U.S.
- 8.3.4.1. U.S.: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.5. Gastroparesis Drugs Market - Canada
- 8.3.5.1. Canada: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4. Gastroparesis Drugs Market - Europe
- 8.4.1. Europe: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.2. Europe.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.3. Europe: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.4. Gastroparesis Drugs Market - UK
- 8.4.4.1. UK: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.4.3. UK: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.5. Gastroparesis Drugs Market - France
- 8.4.5.1. France: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.5.2. France.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.5.3. France: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.6. Gastroparesis Drugs Market - Germany
- 8.4.6.1. Germany: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.7. Gastroparesis Drugs Market - Italy
- 8.4.7.1. Italy: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.8. Gastroparesis Drugs Market - Spain
- 8.4.8.1. Spain: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.9. Gastroparesis Drugs Market - Netherlands
- 8.4.9.1. Netherlands: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.10. Gastroparesis Drugs Market - Russia
- 8.4.10.1. Russia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.5. Gastroparesis Drugs Market - Asia Pacific
- 8.5.1. Asia Pacific: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.4. Gastroparesis Drugs Market - China
- 8.5.4.1. China: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.5.4.2. China.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.5.4.3. China: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.5. Gastroparesis Drugs Market - India
- 8.5.5.1. India: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.5.5.2. India.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.5.5.3. India: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.6. Gastroparesis Drugs Market - Malaysia
- 8.5.6.1. Malaysia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.7. Gastroparesis Drugs Market - Japan
- 8.5.7.1. Japan: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.8. Gastroparesis Drugs Market - Indonesia
- 8.5.8.1. Indonesia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.9. Gastroparesis Drugs Market - South Korea
- 8.5.9.1. South Korea: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.6. Gastroparesis Drugs Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.4. Gastroparesis Drugs Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.5. Gastroparesis Drugs Market - UAE
- 8.6.5.1. UAE: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.6. Gastroparesis Drugs Market - Israel
- 8.6.6.1. Israel: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.7. Gastroparesis Drugs Market - South Africa
- 8.6.7.1. South Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.7. Gastroparesis Drugs Market - Latin America
- 8.7.1. Latin America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.7.3. Latin America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.4. Gastroparesis Drugs Market - Mexico
- 8.7.4.1. Mexico: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.5. Gastroparesis Drugs Market - Brazil
- 8.7.5.1. Brazil: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.6. Gastroparesis Drugs Market - Argentina
- 8.7.6.1. Argentina: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott Laboratories (US)
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. AbbVie Inc. (US)
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Allergan Inc. (US)
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Evoke Pharma (US)
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Medtronic Plc (Ireland)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Neurogastrx Inc. (US)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Pfizer Inc. (US)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Rhythm Pharmaceuticals Inc. (US)
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Salix Pharmaceuticals (US)
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. TEVA Pharmaceutical (Israel)
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Vanda Pharmaceuticals Inc. (US)
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
